NASD · Healthcare · Biotechnology · USA
Nurix Therapeutics Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Nurix Therapeutics is a clinical stage biopharmaceutical company developing targeted protein degradation medicines for cancer and inflammatory diseases. Its three investigational drug candidates include bexobrutideg, a BTK degrader; zelebrudomide, a dual BTK and transcription factor degrader; and NX-1607, a CBL-B inhibitor.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Nurix Therapeutics Inc stock.
Undervalued: intrinsic value $62.69 per share, market price $14.24, margin of safety 77.3% (as of 2026-11-17).
Discounting its cash flows at 12.8% (average of 3 methods) values the shares at $62.69; the price of $14.24 is 77% below that value, and 66% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
NRIX is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 12.8% (average of 3 methods) values the shares at $62.69; the price of $14.24 is 77% below that value, and 66% of that value comes from beyond year five.
$62.69 per share (as of the 2026-11-17 close), against a market price of $14.24. That is a margin of safety of 77.3%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.